[
  {
    "ts": null,
    "headline": "S&P 500 Posts Weekly Gain on Tariff Optimism, Better-Than-Expected Earnings",
    "summary": "The Standard & Poor's 500 index rose 1.7% this week as earnings season kicked off on a largely posit",
    "url": "https://finnhub.io/api/news?id=0d039924080216add766b39758d14090bf2b2385293f24999500ca5b8f9afd69",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760733951,
      "headline": "S&P 500 Posts Weekly Gain on Tariff Optimism, Better-Than-Expected Earnings",
      "id": 137135671,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Standard & Poor's 500 index rose 1.7% this week as earnings season kicked off on a largely posit",
      "url": "https://finnhub.io/api/news?id=0d039924080216add766b39758d14090bf2b2385293f24999500ca5b8f9afd69"
    }
  },
  {
    "ts": null,
    "headline": "J&J’s Tecvayli-Darzalex trumps SoC in multiple myeloma",
    "summary": "If the combination were to be approved, Tecvayli would expand out from its traditional role in fourth line treatment and beyond.",
    "url": "https://finnhub.io/api/news?id=80b12c0e0a60df49f3288cac682f740d29ffe2b5886537152d7bac5697218051",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760718027,
      "headline": "J&J’s Tecvayli-Darzalex trumps SoC in multiple myeloma",
      "id": 137127519,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If the combination were to be approved, Tecvayli would expand out from its traditional role in fourth line treatment and beyond.",
      "url": "https://finnhub.io/api/news?id=80b12c0e0a60df49f3288cac682f740d29ffe2b5886537152d7bac5697218051"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?",
    "summary": "JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.",
    "url": "https://finnhub.io/api/news?id=c80dc98882d67c760939c3c40cce52481a23d1b0d066f366406a84fa547965d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760717460,
      "headline": "Should You Buy, Sell or Hold J&J Stock After Robust Q3 Earnings?",
      "id": 137127520,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.",
      "url": "https://finnhub.io/api/news?id=c80dc98882d67c760939c3c40cce52481a23d1b0d066f366406a84fa547965d1"
    }
  },
  {
    "ts": null,
    "headline": "Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors",
    "summary": "BOSTON, October 17, 2025--Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors",
    "url": "https://finnhub.io/api/news?id=45ccd842f79bf83b550dd1ebda86b9b0bb17e3e6a923f046a419adf9ceb58edc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760707440,
      "headline": "Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors",
      "id": 137125589,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "BOSTON, October 17, 2025--Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors",
      "url": "https://finnhub.io/api/news?id=45ccd842f79bf83b550dd1ebda86b9b0bb17e3e6a923f046a419adf9ceb58edc"
    }
  },
  {
    "ts": null,
    "headline": "J&J Myeloma Combo Hits Late-Stage Goal",
    "summary": "Combo beats investigator choice in relapsed setting",
    "url": "https://finnhub.io/api/news?id=10ddc302fca52e9da2e9c46be55aa01fab6dddc5d00f23bb78ab0df32f14d072",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760703234,
      "headline": "J&J Myeloma Combo Hits Late-Stage Goal",
      "id": 137125685,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Combo beats investigator choice in relapsed setting",
      "url": "https://finnhub.io/api/news?id=10ddc302fca52e9da2e9c46be55aa01fab6dddc5d00f23bb78ab0df32f14d072"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: American Express beats estimates, EssilorLuxottica stock surges as focus turns to regional bank earnings",
    "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
    "url": "https://finnhub.io/api/news?id=a0f0e795f70e788148a98c919047799b817afe11a7d13c90b0264c2a164589f4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760703163,
      "headline": "Earnings live: American Express beats estimates, EssilorLuxottica stock surges as focus turns to regional bank earnings",
      "id": 137125633,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Third quarter earnings season is just beginning, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.",
      "url": "https://finnhub.io/api/news?id=a0f0e795f70e788148a98c919047799b817afe11a7d13c90b0264c2a164589f4"
    }
  },
  {
    "ts": null,
    "headline": "HistoSonics raises $250m to support commercial expansion",
    "summary": "The funding tranche follows HistoSonics’ $2.25bn acquisition by an investor consortium in August.",
    "url": "https://finnhub.io/api/news?id=cc720de180d311f348ba846c6aaae99df999a53441c6fe9a32d39fa5eb625f23",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760700892,
      "headline": "HistoSonics raises $250m to support commercial expansion",
      "id": 137125687,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The funding tranche follows HistoSonics’ $2.25bn acquisition by an investor consortium in August.",
      "url": "https://finnhub.io/api/news?id=cc720de180d311f348ba846c6aaae99df999a53441c6fe9a32d39fa5eb625f23"
    }
  },
  {
    "ts": null,
    "headline": "Ulta Beauty names Christopher DelOrefice as new CFO",
    "summary": "Chris Lialios will continue as interim CFO until DelOrefice assumes the position in December 2025",
    "url": "https://finnhub.io/api/news?id=de863fa96f6d09631106ea42d33a45018940aee2531388c76fff8f3958e23e78",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760692292,
      "headline": "Ulta Beauty names Christopher DelOrefice as new CFO",
      "id": 137125689,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Chris Lialios will continue as interim CFO until DelOrefice assumes the position in December 2025",
      "url": "https://finnhub.io/api/news?id=de863fa96f6d09631106ea42d33a45018940aee2531388c76fff8f3958e23e78"
    }
  },
  {
    "ts": null,
    "headline": "Cullinan Therapeutics: Worthy Of A Small Position",
    "summary": "Cullinan Therapeutics trades near cash after a major drop, with pipeline risks but upside from CLN-978 and Zipalertinib trials. Read why CGEM stock is a buy.",
    "url": "https://finnhub.io/api/news?id=0ff6cf42130fc3fc9b40c647542d94b513a53386dd0544efb978c5a6013c93ce",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760684507,
      "headline": "Cullinan Therapeutics: Worthy Of A Small Position",
      "id": 137124660,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1295160689/image_1295160689.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Cullinan Therapeutics trades near cash after a major drop, with pipeline risks but upside from CLN-978 and Zipalertinib trials. Read why CGEM stock is a buy.",
      "url": "https://finnhub.io/api/news?id=0ff6cf42130fc3fc9b40c647542d94b513a53386dd0544efb978c5a6013c93ce"
    }
  },
  {
    "ts": null,
    "headline": "HistoSonics raises $250M to expand use of noninvasive cancer therapy",
    "summary": "The company raised money from Bezos Expeditions, Thiel Bio and other investors to fund the commercial and clinical expansion of its technology.",
    "url": "https://finnhub.io/api/news?id=9d10f4d2ba7104a1f47458c9a6eb45c377b0742eaab48062383312a269585cad",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760680468,
      "headline": "HistoSonics raises $250M to expand use of noninvasive cancer therapy",
      "id": 137125690,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The company raised money from Bezos Expeditions, Thiel Bio and other investors to fund the commercial and clinical expansion of its technology.",
      "url": "https://finnhub.io/api/news?id=9d10f4d2ba7104a1f47458c9a6eb45c377b0742eaab48062383312a269585cad"
    }
  }
]